Roggwil, May 2, 2022 – The explosive increase in tinnitus patients after recovering from COVID has significantly boosted sales of tinniwell. Already last year, a notable increase in patients was observed in consultations. This subjective observation was supported by a meta-study from the University of Manchester, which found that 14.8% of COVID survivors experienced tinnitus as a form of Long COVID.

For tinniwell, sales in April 2022 alone increased by 323% compared to the previous year. Since Europe and the USA are effectively implementing a strategy of herd immunity (removal of mask mandates, etc.), further multiplication of sales for tinniwell is to be expected. In South Africa, an increase in infections with the new Omicron variants B.4 and B.5 has been recorded since January 2022. Each of these mutations can lead to tinnitus, and the study from the University of Manchester involved patients with up to 4 COVID infections.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015 that has been selling a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG


Ms. Anke Rauterkus (Chief Executive Officer)

Bahnhofplatz 5

9322 Egnach


Switzerland

T. +41 714500668


a.rauterkus@resaphene.ch